Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
AssigneeThe Regents of the University of Colorado
InventorsRoss Kedl, Phillip J. Sanchez, Catherine Haluszczak
Life of this patent
Estimating the term…
Abstract
A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.
Claims60
An immunostimulatory regimen for inducing CD70 expression on dendritic cells and inducing the expansion of CD8+T cells in a subject in need thereof and thereby eliciting an anti-viral immune response comprising administering type I interferon and an immune agonist polypeptide other than said type 1 interferon, and further including the administration of a viral antigen, wherein said regimen does not include the administration of a TLR agonist and further requires that the only immune agonist polypeptide other than said type 1 interferon administered in said immunostimulatory regimen consists of an agonistic CD40L polypeptide or a CD40 agonistic antibody or a CD40 agonistic antibody fragment polypeptide, and further wherein said agonistic CD40L polypeptide, CD40 agonistic antibody or CD40 agonistic antibody fragment and said type 1 interferons are administered in amounts that in combination, but not separately, result in the induction of CD70 expression on dendritic cells.
An immunostimulatory regimen for inducing the expansion of CD8+T cells in a subject in need thereof and eliciting an anti-viral immune response by administering a type 1 interferon and an immune agonist polypeptide other than said type 1 interferon and further including the administration of a viral antigen, wherein said regimen does not include the administration of a TLR agonist and further requires that the only immune agonist polypeptide administered-in said immunostimulatory regimen other than said type 1 interferon consists of a an agonistic CD40L polypeptide or CD40 agonistic antibody or a CD40 agonistic antibody fragment polypeptide and wherein said an agonistic CD40L polypeptide, CD40 agonistic antibody or CD40 agonistic antibody fragment and said type 1 interferon are administered in amounts that in combination, but not separately, result in the expansion of CD8+T cells.
An immunostimulatory therapeutic regimen for inducing primary and memory T cell responses in a subject in need thereof and eliciting an antiviral immune response by administering type 1 interferon and an immune agonist polypeptide other than said type 1 interferon and another further including a viral antigen, wherein said regimen does not include the administration of a TLR agonist and further requires that the only immune agonist polypeptide used in said immunostimulatory regimen other than said type 1 interferon consists of a an agonistic CD40L polypeptide or CD40 agonistic antibody or a CD40 agonistic antibody fragment polypeptide and wherein said an agonistic CD40L polypeptide, CD40 agonistic antibody or CD40 agonistic antibody fragment and said type 1 interferon are administered in amounts that in combination, but not separately, result in a synergistic effect on immunity resulting in enhanced primary and memory CD8+T cell responses specific to the viral antigen.
Dependencies are inferred from the claim text.